Manchester University NHS Foundation Trust (MFT) has been named as one of a very small number of centres in the UK to offer a revolutionary new cancer treatment, widely regarded as the most exciting cancer treatment development in decades.

MFT will be able to offer the ground-breaking treatment to children and adults and is unique in this regard. Within MFT, the treatment will be delivered in Royal Manchester Children’s Hospital and Manchester Royal Infirmary.

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a personalised medicine used to treat patients with certain types of leukaemia and lymphoma. It is a highly complex new type of immunotherapy which involves collecting and using the patients’ own immune cells to target their cancer in a process which is completed over a number of weeks.